Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals is an Australian biopharmaceutical company focused on developing treatments for disorders involving the skin and photoprotection. The company’s research is based on melanocortin peptides, which are designed to stimulate the production of eumelanin, the pigment that helps protect skin from ultraviolet and visible light.

Clinuvel’s primary commercial product is SCENESSE (afamelanotide), an implantable medication approved for the prevention of phototoxic reactions in adult patients with erythropoietic protoporphyria (EPP), a rare inherited disorder that can cause severe pain and skin damage after exposure to light. The treatment is administered through specialist medical centers.

Founded in Australia, Clinuvel has expanded its regulatory and commercial activities across Australia, Europe and the United States. In addition to SCENESSE, the company is researching potential applications of its melanocortin platform in other serious skin and blood-related conditions. Clinuvel is headquartered in Melbourne and is listed on the Australian Securities Exchange, with its shares also traded in the United States.

Key Stats

• Today's Range: $7.28 to $7.52
• 50-Day Range: $7.35 to $7.35
• 52-Week Range: $5.98 to $9.00
• Volume: 36,763 shs
• Average Volume: 3,028 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Consumer Discretionary
• Industry: Diversified Consumer Services
• Sub-Industry: Specialized Consumer Services
• Current Symbol: OTCMKTS:CLVLY
• CIK: 1290877
• Web: www.clinuvel.com
• Phone: (139) 660-4900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A